サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1530984

胃運動障害治療薬市場：世界の産業分析、規模、シェア、成長、動向、2024-2034年予測

Gastric Motility Disorder Drugs Market (Drug Class: Antacids, Antidiarrheals, Calcium-Channel Blockers; and Disorder Type: Upper Digestive Tract and Lower Digestive Tract) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

出版日
ページ情報
英文 178 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
胃運動障害治療薬市場：世界の産業分析、規模、シェア、成長、動向、2024-2034年予測
出版日: 2024年06月12日
発行: Transparency Market Research
ページ情報: 英文 178 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

胃運動障害治療薬市場- 調査範囲

TMRの調査レポート「胃運動障害治療薬の世界市場」は、2024年から2034年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018年から2034年までの世界の胃運動障害治療薬市場の収益と予測を提供しています。また、2024年から2034年までの世界の胃運動障害治療薬市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、胃運動障害治療薬市場を推察しました。

市場スナップショット
2023年の市場規模 576億米ドル
2034年の市場規模 1,027億米ドル
CAGR 5.4%

当レポートでは、世界の胃運動障害治療薬市場の競合情勢について調査しています。世界の胃運動障害治療薬市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTなどが、本レポートで紹介されている世界の胃運動障害治療薬市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 市場分析と予測、2020年～2034年

第5章 主要洞察

  • パイプライン分析
  • 主要製品・ブランド分析
  • 主要M&A
  • COVID-19による産業への影響

第6章 世界の市場分析と予測：薬剤クラス別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：薬剤クラス別、2020年～2034年
    • 制酸剤
    • 下痢止め
    • カルシウム拮抗薬
    • H2ブロッカー
    • その他（プロトンポンプ阻害剤等）
  • 市場の魅力分析：薬剤クラス別

第7章 世界の市場分析と予測：疾患種別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：疾患種別、2020年～2034年
    • 上部消化管
    • 下部消化管
  • 市場の魅力分析：疾患種別

第8章 世界の市場分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：流通チャネル別、2020年～2034年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場の魅力分析：流通チャネル別

第9章 世界の市場分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2020年～2034年
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域別

第10章 北米の市場分析と予測

第11章 欧州の市場分析と予測

第12章 アジア太平洋地域の市場分析と予測

第13章 ラテンアメリカの市場分析と予測

第14章 中東・アフリカの市場分析と予測

第15章 競合情勢

  • 市場企業- 競争マトリックス（企業階層と規模別）
  • 市場シェア分析：企業別（2023年）
  • 企業プロファイル
    • Pfizer Inc.
    • The Takeda Pharmaceutical Company Limited
    • Janssen Pharmaceuticals
    • Sun Pharmaceutical Industries Ltd.
    • AbbVie Inc.
    • Boehringer Ingelheim
    • Eli Lilly and Company
    • The Bristol-Myers Squibb Company
    • Daiichi Sankyo Company, Limited
    • Bausch Health Companies Inc.
    • Mallinckrodt Pharmaceuticals
    • Endo International plc
    • Eisai Co. Ltd.
    • Ferring Pharmaceuticals
    • UCB
図表

List of Tables

  • Table 01: Global Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 02: Global Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Disorder Type, 2020-2034
  • Table 03: Global Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 04: Global Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Region, 2020-2034
  • Table 05: North America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Country, 2020-2034
  • Table 06: North America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 07: North America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Disorder Type, 2020-2034
  • Table 08: North America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 09: Europe Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 10: Europe Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 11: Europe Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Disorder Type, 2020-2034
  • Table 12: Europe Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 13: Asia Pacific Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Asia Pacific Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 15: Asia Pacific Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Disorder Type, 2020-2034
  • Table 16: Asia Pacific Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 17: Latin America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 18: Latin America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 19: Latin America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Disorder Type, 2020-2034
  • Table 20: Latin America Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 21: Middle East & Africa Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Middle East & Africa Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 23: Middle East & Africa Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Disorder Type, 2020-2034
  • Table 24: Middle East & Africa Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

List of Figures

  • Figure 01: Global Gastric Motility Disorder Drugs Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
  • Figure 02: Global Gastric Motility Disorder Drugs Market Revenue (US$ Bn), by Drug Class, 2023
  • Figure 03: Global Gastric Motility Disorder Drugs Market Value Share, by Drug Class, 2023
  • Figure 04: Global Gastric Motility Disorder Drugs Market Revenue (US$ Bn), by Disorder Type, 2023
  • Figure 05: Global Gastric Motility Disorder Drugs Market Value Share, by Disorder Type, 2023
  • Figure 06: Global Gastric Motility Disorder Drugs Market Revenue (US$ Bn), by Distribution Channel, 2023
  • Figure 07: Global Gastric Motility Disorder Drugs Market Value Share, by Distribution Channel, 2023
  • Figure 08: Global Gastric Motility Disorder Drugs Market Value Share, by Region, 2023
  • Figure 09: Global Gastric Motility Disorder Drugs Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 10: Global Gastric Motility Disorder Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 11: Global Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 12: Global Gastric Motility Disorder Drugs Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 13: Global Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Disorder Type, 2024-2034
  • Figure 14: Global Gastric Motility Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 15: Global Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 16: Global Gastric Motility Disorder Drugs Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 17: Global Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 18: North America Gastric Motility Disorder Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 19: North America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 20: North America Gastric Motility Disorder Drugs Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 21: North America Gastric Motility Disorder Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 22: North America Gastric Motility Disorder Drugs Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 23: North America Gastric Motility Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 24: North America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 25: North America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Disorder Type, 2024-2034
  • Figure 26: North America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 27: Europe Gastric Motility Disorder Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 28: Europe Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 29: Europe Gastric Motility Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 30: Europe Gastric Motility Disorder Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 31: Europe Gastric Motility Disorder Drugs Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 32: Europe Gastric Motility Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 33: Europe Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 34: Europe Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Disorder Type, 2024-2034
  • Figure 35: Europe Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 36: Asia Pacific Gastric Motility Disorder Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 37: Asia Pacific Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 38: Asia Pacific Gastric Motility Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 39: Asia Pacific Gastric Motility Disorder Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 40: Asia Pacific Gastric Motility Disorder Drugs Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 41: Asia Pacific Gastric Motility Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 42: Asia Pacific Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 43: Asia Pacific Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Disorder Type, 2024-2034
  • Figure 44: Asia Pacific Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 45: Latin America Gastric Motility Disorder Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 46: Latin America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 47: Latin America Gastric Motility Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 48: Latin America Gastric Motility Disorder Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 49: Latin America Gastric Motility Disorder Drugs Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 50: Latin America Gastric Motility Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 51: Latin America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 52: Latin America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Disorder Type, 2024-2034
  • Figure 53: Latin America Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 54: Middle East & Africa Gastric Motility Disorder Drugs Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 55: Middle East & Africa Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 56: Middle East & Africa Gastric Motility Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 57: Middle East & Africa Gastric Motility Disorder Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 58: Middle East & Africa Gastric Motility Disorder Drugs Market Value Share Analysis, by Disorder Type, 2023 and 2034
  • Figure 59: Middle East & Africa Gastric Motility Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 60: Middle East & Africa Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 61: Middle East & Africa Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Disorder Type, 2024-2034
  • Figure 62: Middle East & Africa Gastric Motility Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2024-2034
目次
Product Code: TMRGL86200

Gastric Motility Disorder Drugs Market - Scope of Report

TMR's report on the global gastric motility disorder drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global gastric motility disorder drugs market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global gastric motility disorder drugs market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the gastric motility disorder drugs market.

Market Snapshot
Market Value in 2023US$ 57.6 Bn
Market Value in 2034US$ 102.7 Bn
CAGR5.4%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global gastric motility disorder drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global gastric motility disorder drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global gastric motility disorder drugs market.

The report delves into the competitive landscape of the global gastric motility disorder drugs market. Key players operating in the global gastric motility disorder drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global gastric motility disorder drugs market profiled in this report.

Key Questions Answered in Global gastric motility disorder drugs Market Report:

  • What is the sales/revenue generated by gastric motility disorder drugs across all regions during the forecast period?
  • What are the opportunities in the global gastric motility disorder drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Gastric Motility Disorder Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global gastric motility disorder drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global gastric motility disorder drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global gastric motility disorder drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Gastric Motility Disorder Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Gastric Motility Disorder Drugs Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product /Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Gastric Motility Disorder Drugs Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2020-2034
    • 6.3.1. Antacids
    • 6.3.2. Antidiarrheals
    • 6.3.3. Calcium-channel Blockers
    • 6.3.4. H2 Blockers
    • 6.3.5. Others (Proton Pump Inhibitors, etc.)
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Gastric Motility Disorder Drugs Market Analysis and Forecast, by Disorder Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Disorder Type, 2020-2034
    • 7.3.1. Upper Digestive Tract
      • 7.3.1.1. Achalasia
      • 7.3.1.2. Gastroesophageal Reflux Disease (GERD)
      • 7.3.1.3. Gastroparesis
      • 7.3.1.4. Dumping Syndrome
    • 7.3.2. Lower Digestive Tract
      • 7.3.2.1. Intestinal Pseudo-obstruction
      • 7.3.2.2. Small Intestinal bacterial Overgrowth (SIBO)
      • 7.3.2.3. Pelvic Dyssynergia
      • 7.3.2.4. Hirschsprung's Disease
  • 7.4. Market Attractiveness Analysis, by Disorder Type

8. Global Gastric Motility Disorder Drugs Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Gastric Motility Disorder Drugs Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020-2034
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Gastric Motility Disorder Drugs Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Drug Class, 2020-2034
    • 10.3.1. Antacids
    • 10.3.2. Antidiarrheals
    • 10.3.3. Calcium-channel Blockers
    • 10.3.4. H2 Blockers
    • 10.3.5. Others (Proton Pump Inhibitors, etc.)
  • 10.4. Market Value Forecast, by Disorder Type, 2020-2034
    • 10.4.1. Upper Digestive Tract
      • 10.4.1.1. Achalasia
      • 10.4.1.2. Gastroesophageal Reflux Disease (GERD)
      • 10.4.1.3. Gastroparesis
      • 10.4.1.4. Dumping Syndrome
    • 10.4.2. Lower Digestive Tract
      • 10.4.2.1. Intestinal Pseudo-obstruction
      • 10.4.2.2. Small Intestinal bacterial Overgrowth (SIBO)
      • 10.4.2.3. Pelvic Dyssynergia
      • 10.4.2.4. Hirschsprung's Disease
  • 10.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Retail Pharmacies
    • 10.5.3. Online Pharmacies
  • 10.6. Market Value Forecast, by Country, 2020-2034
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Drug Class
    • 10.7.2. By Disorder Type
    • 10.7.3. By Distribution Channel
    • 10.7.4. By Country

11. Europe Gastric Motility Disorder Drugs Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Drug Class, 2020-2034
    • 11.3.1. Antacids
    • 11.3.2. Antidiarrheals
    • 11.3.3. Calcium-channel Blockers
    • 11.3.4. H2 Blockers
    • 11.3.5. Others (Proton Pump Inhibitors, etc.)
  • 11.4. Market Value Forecast, by Disorder Type, 2020-2034
    • 11.4.1. Upper Digestive Tract
      • 11.4.1.1. Achalasia
      • 11.4.1.2. Gastroesophageal Reflux Disease (GERD)
      • 11.4.1.3. Gastroparesis
      • 11.4.1.4. Dumping Syndrome
    • 11.4.2. Lower Digestive Tract
      • 11.4.2.1. Intestinal Pseudo-obstruction
      • 11.4.2.2. Small Intestinal bacterial Overgrowth (SIBO)
      • 11.4.2.3. Pelvic Dyssynergia
      • 11.4.2.4. Hirschsprung's Disease
  • 11.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Retail Pharmacies
    • 11.5.3. Online Pharmacies
  • 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Drug Class
    • 11.7.2. By Disorder Type
    • 11.7.3. By Distribution Channel
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Gastric Motility Disorder Drugs Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Drug Class, 2020-2034
    • 12.3.1. Antacids
    • 12.3.2. Antidiarrheals
    • 12.3.3. Calcium-channel Blockers
    • 12.3.4. H2 Blockers
    • 12.3.5. Others (Proton Pump Inhibitors, etc.)
  • 12.4. Market Value Forecast, by Disorder Type, 2020-2034
    • 12.4.1. Upper Digestive Tract
      • 12.4.1.1. Achalasia
      • 12.4.1.2. Gastroesophageal Reflux Disease (GERD)
      • 12.4.1.3. Gastroparesis
      • 12.4.1.4. Dumping Syndrome
    • 12.4.2. Lower Digestive Tract
      • 12.4.2.1. Intestinal Pseudo-obstruction
      • 12.4.2.2. Small Intestinal bacterial Overgrowth (SIBO)
      • 12.4.2.3. Pelvic Dyssynergia
      • 12.4.2.4. Hirschsprung's Disease
  • 12.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.5.1. Hospital Pharmacies
    • 12.5.2. Retail Pharmacies
    • 12.5.3. Online Pharmacies
  • 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Drug Class
    • 12.7.2. By Disorder Type
    • 12.7.3. By Distribution Channel
    • 12.7.4. By Country/Sub-region

13. Latin America Gastric Motility Disorder Drugs Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Drug Class, 2020-2034
    • 13.3.1. Antacids
    • 13.3.2. Antidiarrheals
    • 13.3.3. Calcium-channel Blockers
    • 13.3.4. H2 Blockers
    • 13.3.5. Others (Proton Pump Inhibitors, etc.)
  • 13.4. Market Value Forecast, by Disorder Type, 2020-2034
    • 13.4.1. Upper Digestive Tract
      • 13.4.1.1. Achalasia
      • 13.4.1.2. Gastroesophageal Reflux Disease (GERD)
      • 13.4.1.3. Gastroparesis
      • 13.4.1.4. Dumping Syndrome
    • 13.4.2. Lower Digestive Tract
      • 13.4.2.1. Intestinal Pseudo-obstruction
      • 13.4.2.2. Small Intestinal bacterial Overgrowth (SIBO)
      • 13.4.2.3. Pelvic Dyssynergia
      • 13.4.2.4. Hirschsprung's Disease
  • 13.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.5.1. Hospitals
    • 13.5.2. Biopharmaceutical Companies
    • 13.5.3. Research Organizations and Academic Institutes
  • 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Drug Class
    • 13.7.2. By Disorder Type
    • 13.7.3. By Distribution Channel
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Gastric Motility Disorder Drugs Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Drug Class, 2020-2034
    • 14.3.1. Antacids
    • 14.3.2. Antidiarrheals
    • 14.3.3. Calcium-channel Blockers
    • 14.3.4. H2 Blockers
    • 14.3.5. Others (Proton Pump Inhibitors, etc.)
  • 14.4. Market Value Forecast, by Disorder Type, 2020-2034
    • 14.4.1. Upper Digestive Tract
      • 14.4.1.1. Achalasia
      • 14.4.1.2. Gastroesophageal Reflux Disease (GERD)
      • 14.4.1.3. Gastroparesis
      • 14.4.1.4. Dumping Syndrome
    • 14.4.2. Lower Digestive Tract
      • 14.4.2.1. Intestinal Pseudo-obstruction
      • 14.4.2.2. Small Intestinal bacterial Overgrowth (SIBO)
      • 14.4.2.3. Pelvic Dyssynergia
      • 14.4.2.4. Hirschsprung's Disease
  • 14.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 14.5.1. Hospital Pharmacies
    • 14.5.2. Retail Pharmacies
    • 14.5.3. Online Pharmacies
  • 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Drug Class
    • 14.7.2. By Disorder Type
    • 14.7.3. By Distribution Channel
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2023)
  • 15.3. Company Profiles
    • 15.3.1. Pfizer Inc.
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. The Takeda Pharmaceutical Company Limited
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Janssen Pharmaceuticals
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Sun Pharmaceutical Industries Ltd.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. AbbVie Inc.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Boehringer Ingelheim
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Eli Lilly and Company
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. The Bristol-Myers Squibb Company
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Daiichi Sankyo Company, Limited
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Bausch Health Companies Inc.
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview
    • 15.3.11. Mallinckrodt Pharmaceuticals
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. SWOT Analysis
      • 15.3.11.4. Financial Overview
      • 15.3.11.5. Strategic Overview
    • 15.3.12. Endo International plc
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Product Portfolio
      • 15.3.12.3. SWOT Analysis
      • 15.3.12.4. Financial Overview
      • 15.3.12.5. Strategic Overview
    • 15.3.13. Eisai Co. Ltd.
      • 15.3.13.1. Company Overview
      • 15.3.13.2. Product Portfolio
      • 15.3.13.3. SWOT Analysis
      • 15.3.13.4. Financial Overview
      • 15.3.13.5. Strategic Overview
    • 15.3.14. Ferring Pharmaceuticals
      • 15.3.14.1. Company Overview
      • 15.3.14.2. Product Portfolio
      • 15.3.14.3. SWOT Analysis
      • 15.3.14.4. Financial Overview
      • 15.3.14.5. Strategic Overview
    • 15.3.15. UCB
      • 15.3.15.1. Company Overview
      • 15.3.15.2. Product Portfolio
      • 15.3.15.3. SWOT Analysis
      • 15.3.15.4. Financial Overview
      • 15.3.15.5. Strategic Overview